Altimmune, Inc.
US ˙ NasdaqGM ˙ US02155H2004

Introduction

This page provides a comprehensive analysis of the known insider trading history of Matthew Scott Harris. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Matthew Scott Harris has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ALT / Altimmune, Inc. Chief Medical Officer 16,087
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Matthew Scott Harris. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ALT / Altimmune, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALT / Altimmune, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2023-03-23 ALT Harris Matthew Scott 10,000 4.2200 10,000 4.2200 42,200 341 13.8100 95,900 227.25

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALT / Altimmune, Inc. Insider Trades
Insider Sales ALT / Altimmune, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALT / Altimmune, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALT / Altimmune, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Matthew Scott Harris as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-04 2025-07-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 2,018 16,087 14.34 3.14 6,337 50,513
2025-03-11 2025-03-07 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
G - Gift -67,787 14,069 -82.81
2025-02-03 2025-02-02 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -2,708 81,856 -3.20 6.64 -17,981 543,524
2025-02-03 2025-02-02 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 7,775 84,564 10.13
2025-02-03 2025-02-01 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -2,109 76,789 -2.67 6.64 -14,004 509,879
2025-02-03 2025-02-01 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 6,166 78,898 8.48
2025-02-03 2025-01-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 1,905 72,732 2.69 5.18 9,868 376,752
2025-02-03 2025-01-30 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -3,173 70,827 -4.29 7.00 -22,211 495,789
2025-02-03 2025-01-30 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 9,275 74,000 14.33
2025-01-28 2025-01-25 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -4,994 64,725 -7.16 6.98 -34,858 451,780
2025-01-28 2025-01-25 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 14,600 69,719 26.49
2024-08-01 2024-07-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 1,486 55,119 2.77 5.41 8,039 298,194
2024-02-05 2024-02-02 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -2,332 53,633 -4.17 9.32 -21,734 499,860
2024-02-05 2024-02-02 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 7,775 55,965 16.13
2024-02-05 2024-02-01 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -1,801 48,190 -3.60 9.88 -17,794 476,117
2024-02-05 2024-02-01 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 6,166 49,991 14.07
2024-02-01 2024-01-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 3,257 43,825 8.03 2.69 8,761 117,889
2024-02-01 2024-01-30 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -2,709 40,568 -6.26 9.80 -26,548 397,566
2024-02-01 2024-01-30 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 9,275 43,277 27.28
2023-08-02 2023-07-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 691 34,002 2.07 2.81 1,942 95,546
2023-03-23 2023-03-23 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
P - Purchase 10,000 33,311 42.90 4.22 42,200 140,572
2023-02-06 2023-02-02 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -2,364 23,311 -9.21 15.04 -35,555 350,597
2023-02-06 2023-02-02 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 7,775 25,675 43.44
2023-02-02 2023-02-01 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -2,183 17,900 -10.87 13.78 -30,082 246,662
2023-02-02 2023-02-01 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 6,166 20,083 44.31
2023-02-02 2023-01-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 1,296 13,917 10.27 10.21 13,230 142,072
2022-08-03 2022-07-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 1,076 12,621 9.32 6.86 7,381 86,580
2022-03-02 2022-02-28 4 ALT Altimmune, Inc.
Stock Options (option to buy)
M - Exercise -30,000 31,400 -48.86
2022-03-02 2022-02-28 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
S - Sale X -30,000 11,545 -72.21 7.52 -225,600 86,818
2022-03-02 2022-02-28 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 30,000 41,545 259.85 1.92 57,639 79,820
2022-02-03 2022-02-02 4 ALT Altimmune, Inc.
Restricted Stock Units
A - Award 31,100 31,100
2022-02-03 2022-02-02 4 ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 91,600 91,600
2022-02-03 2022-02-01 4 ALT Altimmune, Inc.
Restricted Stock Units
M - Exercise -6,166 18,498 -25.00
2022-02-03 2022-02-01 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
F - Taxes -2,183 11,545 -15.90 7.98 -17,420 92,129
2022-02-03 2022-02-01 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
M - Exercise 6,166 13,728 81.54
2022-02-03 2022-01-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 1,800 7,562 31.24 6.86 12,348 51,875
2021-08-06 2021-07-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 725 5,762 14.39 7.71 5,589 44,422
2021-02-03 2021-02-01 4 ALT Altimmune, Inc.
Restricted Stock Units
A - Award 24,664 24,664
2021-02-03 2021-02-01 4 ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 90,000 90,000
2021-02-03 2021-01-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 968 5,037 23.79 12.14 11,752 61,149
2020-11-13 2020-11-12 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
S - Sale X -4,015 4,069 -49.67 10.02 -40,230 40,771
2020-08-04 2020-07-31 4 ALT Altimmune, Inc.
Common Stock, par value $0.0001
A - Award 8,084 8,084 1.46 11,803 11,803
2020-01-03 2020-01-02 4 ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 61,400 61,400
2019-09-11 2019-09-09 4 ALT Altimmune, Inc.
Stock Options (option to buy)
A - Award 107,000 107,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)